Literature DB >> 9492747

Review of 10-year results of PCA hip arthroplasty.

D E Hastings1, H Tobin, M Sellenkowitsch.   

Abstract

OBJECTIVE: To assess the long-term results of the PCA uncemented total hip replacement.
DESIGN: A prospective nonrandomized clinical trial. Follow-up ranged from 8 to 11 years (mean 10.3 years).
SETTING: A university hospital. PATIENTS: One hundred consecutive PCA arthroplasties were performed on 89 patients. All operations were supervised by a single surgeon. The patients' status was reviewed between September and November 1996 by an independent observer. Seventy-three total hip replacements were available for review. INTERVENTION: PCA uncemented acetabular and femoral replacement through a lateral surgical approach. MAIN OUTCOME MEASURES: The need for revision, which was classified as failure, and definite 3-zone acetabular radiolucency, which was considered radiologic evidence of loosening.
RESULTS: The time to failure of the acetabulum averaged 8 years. Femoral failure occurred in 3 patients an average of 4 years postoperatively. The overall failure rate for the acetabulum was 13% and for the femur 7%.
CONCLUSIONS: The acetabular failure rate is unacceptably high. Patients who have had hip replacement with the PCA prosthesis should be followed over the long term.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9492747      PMCID: PMC3950061     

Source DB:  PubMed          Journal:  Can J Surg        ISSN: 0008-428X            Impact factor:   2.089


  2 in total

1.  Long-term results of total hip arthroplasty with an extensively porous coated stem in patients younger than 45 years old.

Authors:  Joon Soon Kang; Kyong Ho Moon; Seung Rim Park; Seong Wook Choi
Journal:  Yonsei Med J       Date:  2009-12-29       Impact factor: 2.759

2.  A comparative study of "plasmacup" and "porous-coated" acetabular components: survival after 10 to 12 years of follow-up.

Authors:  José Ricardo Negreiros Vicente; Carlos Antonio Soares Ulhoa; Marcio Katz; Renato Dainesi Addeo; Alberto Tesconi Croci
Journal:  Clinics (Sao Paulo)       Date:  2010       Impact factor: 2.365

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.